Celldex Therapeutics, Inc. $CLDX Stock Purchased by Candriam S.C.A.

Key Points

• Candriam S.C.A. increased its Celldex stake by 7.8% in the third quarter, adding 37,351 shares to reach 518,476 shares, valued at about $16.9 million.
• Celldex reported a quarterly loss of $0.96 per share, beating the $1.02 loss analysts expected, while revenue of $0.40 million fell short of the $0.72 million consensus estimate.
• Analyst sentiment was broadly positive: 11 analysts rated the stock Buy, one Hold, and one Sell; the consensus price target was $63.08.

Candriam S.C.A. raised its holdings in shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX - Free Report) by 7.8% during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 518,476 shares of the biopharmaceutical company's stock after purchasing an additional 37,351 shares during the period. Candriam S.C.A. owned 0.66% of Celldex Therapeutics worth $16,865,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds also recently modified their holdings of CLDX. Mirae Asset Global Investments Co. Ltd. acquired a new position in Celldex Therapeutics in the third quarter valued at approximately $42,000. Nykredit A S bought a new position in Celldex Therapeutics in the second quarter valued at approximately $67,000. Sterling Capital Management LLC boosted its stake in Celldex Therapeutics by 355.2% in the third quarter. Sterling Capital Management LLC now owns 2,376 shares of the biopharmaceutical company's stock valued at $77,000 after acquiring an additional 1,854 shares during the last quarter. State of Wyoming boosted its stake in Celldex Therapeutics by 347.3% in the third quarter. State of Wyoming now owns 2,943 shares of the biopharmaceutical company's stock valued at $95,000 after acquiring an additional 2,285 shares during the last quarter. Finally, Abel Hall LLC grew its holdings in Celldex Therapeutics by 6.8% during the 3rd quarter. Abel Hall LLC now owns 6,237 shares of the biopharmaceutical company's stock worth $202,000 after acquiring an additional 399 shares during the period.

Celldex Therapeutics Price Performance

Shares of CLDX stock opened at $29.87 on Monday. Celldex Therapeutics, Inc. has a 12-month low of $22.10 and a 12-month high of $45.14. The firm has a market capitalization of $2.35 billion, a price-to-earnings ratio of -6.95 and a beta of 1.04. The firm has a fifty day moving average of $32.93 and a 200-day moving average of $32.68.

Celldex Therapeutics (NASDAQ:CLDX - Get Free Report) last posted its earnings results on Thursday, November 5th. The biopharmaceutical company reported ($0.96) earnings per share for the quarter, topping the consensus estimate of ($1.02) by $0.06. The business had revenue of $0.40 million for the quarter, compared to the consensus estimate of $0.72 million. Research analysts expect that Celldex Therapeutics, Inc. will post -4.17 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several analysts have commented on the stock. Wells Fargo & Company upped their target price on shares of Celldex Therapeutics from $48.00 to $72.00 and gave the company an "overweight" rating in a research report on Wednesday, July 29th. Guggenheim raised their price target on Celldex Therapeutics from $90.00 to $100.00 and gave the stock a "buy" rating in a research report on Monday, July 20th. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Celldex Therapeutics in a research note on Thursday, October 15th. Wall Street Zen upgraded Celldex Therapeutics from a "strong sell" rating to a "sell" rating in a report on Sunday, July 12th. Finally, Canaccord Genuity Group dropped their price objective on Celldex Therapeutics from $62.00 to $60.00 and set a "buy" rating for the company in a report on Wednesday, July 22nd. Eleven equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, Celldex Therapeutics has an average rating of "Moderate Buy" and a consensus price target of $63.08.

Celldex Therapeutics Profile

Celldex Therapeutics, Inc is a clinical-stage biopharmaceutical company that develops antibody-based treatments for inflammatory diseases and cancer. Its research focuses on targets involved in immune responses and the activity of mast cells.

The company's lead candidate, barzolvolimab, is an antibody that targets the KIT receptor. Celldex is studying it for chronic urticaria and other conditions associated with mast-cell activity.

Celldex also has early-stage oncology programs that investigate antibody therapies designed to affect immune pathways.

Want to see what other hedge funds are holding CLDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Celldex Therapeutics, Inc. (NASDAQ:CLDX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.